NirvaMed Overview
- Year Founded
-
2010
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
Series A3
- Investors
-
6
NirvaMed General Information
Description
Developer of a patented breakthrough therapy designed to reduce heart muscle damage suffered by heart attack patients. The company's system provides treatment for myocardial infarction attacks through its proprietary percutaneous catheter, which substantially reduces muscle death and redefines the standard of care, enabling medical professionals to reduce health disparity in communities.
Contact Information
Website
www.nirvamedical.comCorporate Office
- 8500 Pillsbury Avenue South
- Minneapolis, MN 55420
- United States
Corporate Office
- 8500 Pillsbury Avenue South
- Minneapolis, MN 55420
- United States
NirvaMed Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
4. Later Stage VC (Series A3) | 01-Mar-2023 | Completed | Generating Revenue | |||
3. Later Stage VC (Series B) | 11-Jun-2021 | Cancelled | Generating Revenue | |||
2. Later Stage VC (Series A2) | 07-Sep-2019 | $4.88M | $5.13M | Completed | Generating Revenue | |
1. Angel (individual) | 20-Apr-2015 | $260K | $260K | Completed | Generating Revenue |
NirvaMed Comparisons
Industry
Financing
Details
NirvaMed Competitors (1)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
FocalCool | Corporation | Mullica Hill, NJ |
NirvaMed Patents
NirvaMed Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-11173239-B2 | Localized therapy delivery and local organ protection | Active | 02-Feb-2010 | ||
US-20190275231-A1 | Localized therapy delivery and local organ protection | Active | 02-Feb-2010 | ||
US-20160175513-A1 | Localized therapy delivery and local organ protection | Active | 02-Feb-2010 | ||
US-10195333-B2 | Localized therapy delivery and local organ protection | Active | 02-Feb-2010 | ||
US-9308310-B2 | Localized therapy delivery and local organ protection | Active | 02-Feb-2010 | A61M1/3613 |
NirvaMed Signals
NirvaMed Investors (6)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
Bangkok Dusit Medical Services | Corporation | Minority | ||
GC Ventures | Corporate Venture Capital | Minority | ||
PTT Global Chemical | Corporation | Minority | ||
Samart Corp | Corporation | Minority | ||
SeaX Ventures | Venture Capital | Minority |
NirvaMed FAQs
-
When was NirvaMed founded?
NirvaMed was founded in 2010.
-
Where is NirvaMed headquartered?
NirvaMed is headquartered in Minneapolis, MN.
-
What is the size of NirvaMed?
NirvaMed has 4 total employees.
-
What industry is NirvaMed in?
NirvaMed’s primary industry is Therapeutic Devices.
-
Is NirvaMed a private or public company?
NirvaMed is a Private company.
-
What is NirvaMed’s current revenue?
The current revenue for NirvaMed is
. -
How much funding has NirvaMed raised over time?
NirvaMed has raised $5.13M.
-
Who are NirvaMed’s investors?
Bangkok Dusit Medical Services, GC Ventures, PTT Global Chemical, Samart Corp, and SeaX Ventures are 5 of 6 investors who have invested in NirvaMed.
-
Who are NirvaMed’s competitors?
FocalCool is a competitor of NirvaMed.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »